The company merged with Aierjian and has a rich product line. Including hematoma, mainstream areas related to immunity. Medical Beauty, Ophthalmology is responsible for the new product Vinetok. The product has two indications, AML and CLL. It is developed in cooperation with Roche. The product line is purchased for 1 billion US dollars. The resources are sufficient and the product is competitive.
*The information listed in this article refers to products that have not been approved in China. This information is for information sharing purposes only, and it should not be construed that these products will be registered or approved in China.
AbbVie blood tumor products are expected to change the treatment of leukemia patients in the future
On December 8, AbbVie announced its blood tumor product VENCLEXTA®/VENCLYXTO® (venetoclax) combined with rituximab treatment plan (VenR) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) The long-term data of the data is post-hoc
analysis. The latest data from MURANO, a phase 3 clinical study with an evaluation period of up to 4 years, further confirms that after a fixed course of treatment with this combination regimen, it shows continued clinical benefit. The full results of the study will be published at the 61st Annual Meeting and Exhibition of the American Society of Hematology (ASH).
Dr. Mohammed Zaki, Vice President of AbbVie and Director of Global Hematology R&D, stated:
"These data prove that fixed-course venetoclax treatment can significantly reduce the risk of disease progression and death in patients with chronic lymphocytic leukemia. We will continue to promote the study of venetoclax combined drug regimen and make it the best effect, we will continue Advance clinical research projects that are expected to change the treatment of leukemia patients in the future."
Venetoclax is a pioneering oral B-cell lymphoma factor-2 (Bcl-2) inhibitor. It is part of a collaboration between AbbVie and Rohce. AbbVie is responsible for leading R&D and global commercial promotion.
hematology/oncology doctor, suggestion: it is best to be a person from Tianjin Blood Research Institute